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Architecture of high-affinity
unnatural-base DNA aptamers
toward pharmaceutical applications
Ken-ichiro Matsunaga1,2,3, Michiko Kimoto1,2,3,4, Charlotte Hanson5, Michael Sanford5,
Howard A. Young5 & Ichiro Hirao1,2,3
We present a remodeling method for high-affinity unnatural-base DNA aptamers to augment their
thermal stability and nuclease resistance, for use as drug candidates targeting specific proteins.
Introducing a unique mini-hairpin DNA provides robust stability to unnatural-base DNA aptamers
generated by SELEX using genetic alphabet expansion, without reducing their high affinity. By this
method, >80% of the remodeled DNA aptamer targeting interferon-γ (KD of 33 pM) survived in human
serum at 37 °C after 3 days under our experimental conditions, and sustainably inhibited the biological
activity of interferon-γ.
In clinical medicine, neutralizing antibodies have revolutionized the treatments of numerous diseases and improved
the quality of life for thousands of patients. However, these antibodies occasionally evoke undesirable immune
responses to themselves, and quality control in mass production can be problematic1. Thus, DNA aptamers represent an alternate approach for targeting proteins2–4.
DNA aptamers are oligonucleotides that bind to a variety of targets, such as small molecules, oligosaccharides,
peptides, proteins, and cells. They are generated by an evolutionary engineering method called SELEX, using an
oligonucleotide library with a randomized sequence5,6. Once DNA aptamer sequences are obtained by SELEX,
the aptamers can be chemically synthesized on a large GMP scale, for diagnostic and therapeutic applications.
Nevertheless, no DNA aptamer drugs have been approved yet for clinical use. Only a modified RNA aptamer
(pegaptanib sodium, Macugen) against vascular endothelial cell growth factor-165 (VEGF165) has been approved,
as a treatment for neovascular age-related macular degeneration7.
As clinical candidates, generated DNA or RNA aptamers are initially screened by their biological activity, based
on target affinity, thermal stability, and nuclease resistance. However, the KD values of most aptamers generated
by SELEX are around nM orders, and the aptamers often lack biological activity. Another problem is their low
stability against nucleases, and thus the nucleotide components in aptamers must be protected by chemical modifications4,8–12, such as 2′ -methoxy- and/or 2′ -halide-ribonucleotides or 3′ -bioconjugated oligonucleotides, which
often reduce their affinity and/or increase the production cost. Other versions include RNA aptamers bearing
L-ribose with increased nuclease resistance, as reported by Spiegelmer13, and DNA aptamers containing modified
bases, such as SOMAmer14 and X-aptamer15, with improved aptamer generation success rates. However, with
these methods, the significant augmentation of the aptamer affinities to their targets is still an intractable problem.
We recently developed a new SELEX method to generate high-affinity DNA aptamers, by applying genetic
alphabet expansion using an artificial extra base pair (unnatural base pair)16–18 between the hydrophobic Ds and Px
bases that functions in PCR as a third base pair (SELEX procedure in Fig. 1a). The KD values of Ds-containing DNA
aptamers generated by this method are lower than pM for VEGF165 and 46 ±  8 pM for interferon-γ (IFNγ )18. We
now report the high biological activity of the anti-IFNγ DNA aptamer in cell culture experiments, and an aptamer
remodeling method that greatly increases the thermal stability and nuclease resistance (Fig. 1). The method could
open the door to new unnatural-base DNA aptamer drug candidates for clinical trials.
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Figure 1. Unnatural-base DNA aptamer generation and remodeling toward diagnostic and therapeutic
applications. (a) Generation of unnatural-base DNA aptamers by SELEX involving the Ds–Px pair, and
aptamer remodeling strategy by introducing mini-hairpin DNA. The original aptamer sequences are colored
green, the mini-hairpin regions are red, and the stem region with A–T replaced with G–C is blue. (b) The
secondary structure of an extraordinarily stable mini-hairpin DNA with a GAA loop and the consecutive two or
three G–C base pairs as the stem region. The blue dashed line between the two As indicates the kinked position
of the GCGAAGC fragment. A non-canonical shared G–A base pair is formed in the GAA loop. (c) The tertiary
structure of the mini-hairpin DNA, obtained by NMR spectroscopy22.

Results

Biological activity of the anti-IFNγ DNA aptamer. We confirmed that the high affinity of the aptamers
to their targets is essential for their biological activity, by inhibition experiments using the unnatural-base DNA
aptamer against IFNγ , a cytokine that induces STAT1 phosphorylation in cultured cells19 (Fig. 2a). The mixture
of recombinant human IFNγ (2 ng/ml, ~118 pM as a monomer) and the anti-IFNγ DNA aptamer (50–200 ng/ml,
Fig. 3) was added to the human breast tumor cell line in 10% fetal calf serum, and incubated at 37 °C for 10 min.
The cells were stained intracellularly, using an anti-phospho-STAT1 antibody and FITC-conjugated F(ab′ )2
goat anti-rabbit IgG, and detected by flow cytometry (FACS). The addition of 50 ng/ml (~3 nM) of the original
anti-IFNγ DNA aptamer18 (49-mer, aptamer 49, KD =  46 pM) completely inhibited the STAT1 phosphorylation
(Fig. 2b). In contrast, a conventional DNA aptamer consisting of only the natural bases had no effect (26-mer,
Scientific Reports | 5:18478 | DOI: 10.1038/srep18478
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Figure 2. Inhibition of the interaction between IFNγ and its receptor by anti-IFNγ DNA aptamers.
(a) Schematic illustration of the inhibition of the IFNγ -induced cellular signalling pathway by an anti-IFNγ
DNA aptamer. (b–e) FACS analysis of STAT1 phosphorylation in the presence of each aptamer. Black and red
peaks represent 2 ng/ml of human IFNγ treatment with and without aptamers (b) 50 ng/ml of aptamer 49 for
10 min, (c) 200 ng/ml of aptamer 26 for 10 min, (d) 50 ng/ml of aptamer 49A for 10 min, (e) 50 ng/ml of aptamer
49 overnight), respectively. Grey peaks represent unstimulated cells.

Figure 3. Remodeling strategy of the anti- IFNγ DNA aptamer from aptamer 49 to aptamer 57 mhGC. The
remodeled regions are indicated in red circles with white letters (CGCGAAGCG) and blue circles with yellow
letters (A–T replaced with G–C).

aptamer 26, KD =  16 nM)20 (Fig. 2c). Replacing three Ds bases in aptamer 49 with A (aptamer 49A, KD =  7.2 nM)
also had no inhibitory effect (Fig. 2d). These results revealed that the low KD values (subnanomolar) are the first
threshold for aptamers to exhibit their biological activity and be considered as drug candidates.
The next barrier toward the pharmaceutical application of Ds-containing DNA aptamers is their stability
against nucleases. The Ds-containing DNA aptamers are degraded in serum. For example, aptamer 49 was mostly
degraded after 24 hours at 37 °C in human serum (Fig. 4a), and lost the activity in an overnight assay (Fig. 2e).
The degradation of aptamer 49 was as high as those of single-stranded DNA fragments consisting of only natural
bases (control DNA: ssDNA1 and ssDNA2 50-mer), although a small amount of partially digested fragments of
aptamer 49 seemed to remain, as compared to the control DNA fragments (Supplementary Fig. 1). This slight
nuclease resistance of aptamer 49 might result from its tertiary structure formation, rather than the incorporated
Ds bases. The relatively low thermal stability of aptamer 49 (Thermal melting temperature (Tm) =  37.8 °C) (see
Supplementary Fig. 2) might also affect the degradation.
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Figure 4. Characterization of the original and remodeled unnatural-base DNA aptamers. (a) Original and
(b–d) remodeled anti-IFNγ DNA aptamers (a) aptamer 49, (b) aptamer 58, (c) aptamer 57 mh, (d) aptamer
57 mhGC), characterized by nuclease resistance in 96% human serum at 37 °C (Supplementary Fig. 3), thermal
stability (Supplementary Fig. 2), binding ability analyzed by BIAcore T200 in the presence of 1.25–50 nM IFNγ
(Supplementary Fig. 5), and STAT1 phosphorylation for the inhibition of IFNγ (FACS analysis). Black and
red peaks represent human IFNγ treatment with and without aptamers, respectively. Grey peaks represent
unstimulated cells.

Remodeling the anti-IFNγ DNA aptamer by introducing a mini-hairpin DNA.

To address the
aptamer degradation, we introduced an extraordinarily stable mini-hairpin DNA into the anti-IFNγ DNA
aptamer. Previously, we discovered unique mini-hairpin DNA sequences consisting of a GNA or GNNA loop
(N =  A, G, C or T) and at least two G–C pairs (Fig. 1b and 1c)21–23. The Tm value of a GCGAAGC mini-hairpin
DNA fragment is as high as 78 °C, and the mini-hairpin DNA fragments are remarkably resistant to nucleases.
Furthermore, attaching the mini-hairpin DNA fragment to the 3′ -terminus of other oligonucleotides endows
resistance against 3′ -exonucleases24.
Aptamer 49 was remodeled, according to the scheme shown in Fig. 1a (Remodeling procedure), Fig. 3, and
Supplementary Table 1. First, a mini-hairpin DNA, CGCGAAGCG, including three G–C pairs and a GAA loop
was attached to the 3′ -terminus of aptamer 49 (aptamer 58), for resistance to the 3′ -exonucleases. Second, the
mini-hairpin DNA was replaced with the internal hairpin structure which might not involve the direct interaction
with its target (aptamer 57 mh), to stabilize the entire aptamer tertiary structure and confer endonuclease resistance.
Scientific Reports | 5:18478 | DOI: 10.1038/srep18478
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Our previous studies of aptamer 49 showed that this hairpin loop sequence including Ds is less conserved for the
binding18. Third, all of the A–T pairs in the terminal stem region were replaced with G–C pairs (aptamer 57 mhGC),
to further stabilize the aptamer structure. We presumed that the two Ds bases directly interact with IFNγ , and
other stem or hairpin regions might reinforce the stabilization of the aptamer scaffold.
The high potential of this remodeling strategy was confirmed by the significantly enhanced stability of
the aptamer without affinity reduction, as well as the increased endurance of the inhibitory activity to IFNγ
(Fig. 4). The nuclease resistance and the thermal stability of the remodeled aptamers were improved step by step.
In particular, the Tm value of aptamer 57 mhGC (Tm =  64.2 °C) increased by ~26 °C, relative to that of aptamer
49 (Tm =  37.8 °C) (Fig. 4 and Supplementary Fig. 2). From the first derivations of the Tm measurements, the characteristic melting profiles of the mini-hairpin regions of aptamer 57 mh and aptamer 57 mhGC were observed at
85–90 °C (Supplementary Fig. 2). In addition, the Tm curvature of aptamer 57 mhGC was broadened, as compared
to the other profiles. Thus, the tertiary structure of aptamer 57 mhGC might melt gradually at certain regions.
Importantly, the Tm profiles indicated that aptamer 57 mhGC is much more stable at around 37 °C, relative to the
other aptamers. This observation was confirmed by the increased nuclease resistance of the remodeled aptamers
(Fig. 4 and Supplementary Fig. 3). Finally, more than 80% of aptamer 57 mhGC survived after an incubation in
serum at 37 °C for 3 days.
This remodeling did not affect the aptamer affinity to targets, and the KD value of aptamer 57 mhGC
(KD =  33 pM) was as high as that of aptamer 49 (KD =  46 pM) (Fig. 4). The chi square values for the determination of the KD values using a 1 : 1 complex were relatively large, but were reduced by the remodeling process
(Supplementary Fig. 4). The chi square values of aptamer 49 were 2.7–4.9 using a 1 : 1 complex and 0.6–0.7 using
a heterogeneous ligand complex, indicating the possibility that aptamer 49 adopts two structures, a major one
with high affinity (pM order KD value) and a minor one with low affinity (nM order KD value). In contrast, the chi
square value of aptamer 57 mhGC using a 1 : 1 complex was improved (0.6–1.3). Thus, our remodeling method to
increase the rigidity of the stem regions might unify the tertiary structure of the aptamer and enhance its stability,
without reducing its affinity to targets.
The biological activity was also improved step by step by the remodeling (Fig. 2d, Supplementary Fig. 5). The
IFNγ inhibition using 100 ng/ml (~6.2 nM) of aptamers was clearly enhanced by the remodeling. In particular,
aptamer 57 mhGC completely inhibited the IFNγ activity after an overnight incubation at 37 °C (Fig. 4d), and even
after 3 days (Supplementary Fig. 6).

Discussion

We have presented the remodeling of high-affinity unnatural-base DNA aptamers, which function as alternatives to
antibodies. The remodeled aptamer 57 mhGC targeting IFNγ , in cases where cytokine expression directly contributes to disease pathogenesis25, might be applied to diagnostics and therapeutics. This remodeling process revealed
that sub-nM KD values, as measured by surface plasmon resonance (SPR), might be a pivotal requirement for the
use of nucleic acid aptamers in diagnostic and therapeutic applications. To this end, the thermal stabilities of the
tertiary structures of unnatural-base DNA aptamers must be increased, to confer nuclease resistance at a physiological temperature. Introducing the Ds bases greatly augmented the aptamer affinity to targets, and remodeling
using the mini-hairpin DNA significantly enhanced the thermal stability and nuclease resistance.
Unlike conventional chemical modifications of aptamers, our method using natural oligonucleotides, containing
a few low-toxicity Ds bases26, has a profound effect on aptamer stability, and thus will provide low-cost drug candidates with minimal toxicity. In addition, the mini-hairpin DNA linkage to the 3′-terminus of the terminal stem
region of the aptamers stabilizes them more efficiently, as compared to the conventional 3′ -3′ inverted dT modification used in pegaptanib sodium for the protection of the 3′ -terminus of the aptamer against 3′ -exonucleases.
The 3′ -terminal base of the mini-hairpin DNA also protects the 5′ -terminus of the aptamer, by base stacking with
the 5′ -base of the aptamer (data not shown).
For this remodeling, information about the secondary structures of the aptamers is essential, and can be
obtained by doped selection using a library with partially randomized aptamer sequences18. Although the base
sequences in the stem-loop regions that are essential for direct binding cannot be replaced with mini-hairpin
sequences, most of the A–T pairs in the stem regions of aptamers might be replaced with G-C pairs. This is because
the stem regions in the Ds-containing DNA aptamers are important as a scaffold to facilitate the interaction of the
hydrophobic Ds bases with the target. Thus, this remodeling might be most effective for unnatural-base aptamers,
but could also improve the stability and affinity of some conventional DNA and RNA aptamers.

Methods

Oligonucleotides. DNA fragments were purchased from Gene Design or chemically synthesized with an
Oligonucleotide Synthesizer nS-8 (Gene Design), using phosphoramidite reagents for the natural and Ds bases
(Glen Research). The DNA fragments were purified by gel electrophoresis.
Tm measurements.

UV melting profiles of aptamers were recorded, using a SHIMADZU UV-2450 spectrometer equipped with a temperature controller (TMSPC-8). The absorbance of each sample (2 μ M in 1 mM
KH2PO4, 3 mM Na2HPO4, and 155 mM NaCl, pH 7.4) was monitored at 260 nm from 15 to 95 °C, at a heating
rate of 0.5 °C/min. Each melting temperature was calculated by the first derivative of the melting curve, using the
IGOR Pro software (WaveMetrics, Inc.).

Serum stability analyses. Each DNA aptamer (aptamer 49, aptamer 58, aptamer 57 mh, and aptamer
57 mhGC; final concentration: 2 μ M, the aptamers were initially dissolved in 1× PBS) was incubated in 96%
human serum (Millipore, Lot #NMM1610699) at 37°C. Aliquots (10 μ l) were removed at various time points
from 0 to 72 hours, and degradation was terminated by immediate mixing with 110 μ l of denaturing solution (1×
Scientific Reports | 5:18478 | DOI: 10.1038/srep18478
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TBE containing 10 M urea). Each sample was fractionated by 15% denaturing polyacrylamide gel electrophoresis.
The DNA was stained with SYBR Gold, detected with a bio-imaging analyzer (Fuji Film LAS-4000), and quantified using the Multi Gauge software to determine the intact fraction. The bands at the top (well positions) on the
gel result from the serum, as shown in the lanes without DNA (for only human serum) in Supplementary Fig. 1.

Binding analyses. Binding affinities of DNA aptamers were examined by SPR measurements, using a
BIAcore T200 (GE Healthcare) at 25 °C. Each biotinylated DNA aptamer was diluted to 25 nM in phosphate buffer
(1× PBS; 1 mM KH2PO4, 3 mM Na2HPO4 and 155 mM NaCl, pH 7.4, Gibco), denatured at 95 °C, cooled slowly to
room temperature, and then diluted to 0.5 nM in running buffer (1 × PBS supplemented with 50 mM NaCl (final
NaCl concentration: 205 mM), with 0.05% (vol/vol) Nonidet P-40). To reduce the non-specific binding of the protein, such as to the solid-phase support for the measurements, we measured the KD values with a relatively high
NaCl concentration (Supplementary Fig. 4). Immobilization on a Sensor chip SA (GE Healthcare) was performed
by injecting the DNA solution for 8 min, at a flow rate of 5 μ l min−1 in running buffer. The interaction between the
immobilized DNA aptamer and recombinant human IFNγ (Peprotech) was detected by monitoring injections
of 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 30 nM, and 50 nM IFNγ solutions (diluted with running buffer) in the
Kinetic Injection mode. Measurement conditions: flow rate 100 μ l min−1, protein injection time 150 sec, and
dissociation time 450 sec. After each injection, the sensor surface was regenerated with a 5-μ l injection of 50 mM
NaOH, and the subsequent refolding of the DNA aptamer was accomplished by equilibration with running buffer
for 10 min. To determine the KD values, control sensorgrams of both a reference cell lacking immobilized DNA
fragments on the sensor surface and a measurement with buffer injection were subtracted from each sensorgram
of the aptamers, to cancel bulk effects on the sensor chip and response values attributed to nonspecific adsorption,
and the data were fitted with a 1 : 1 binding model and a heterogeneous ligand model, using the BIAevaluation
T200 software, version 1.0 (GE Healthcare).
Cell lines and IFNγ stimulation. The human breast cancer cell line, MDA-MB-231, was maintained in
Dulbecco’s minimal essential medium (DMEM) (Corning cellgro), supplemented with 10% fetal calf serum (FCS,
Atlanta Biologicals Premium Select Heat inactivated at 56°C, Cat#S11550H Lot # H12123) and 1 × L-glutamine,
penicillin, and streptomycin (Gibco). To prepare MDA-MB-231 cells for stimulation, the cells (1 × 106 cells/ml
in DMEM/10% FCS) were incubated in polystyrene round tubes at 37 °C for 15 min. The cells were centrifuged at
1,200 ×  g for 5 min, and resuspended in DMEM/10% FCS containing 2 ng/ml IFNγ . The cells were stimulated for
10 min at 37 °C, centrifuged, washed once in PBS to stop the reaction, and prepared for FACS analysis.
IFNγ stimulation in the presence of aptamers.

Aptamers were diluted in PBS to a concentration of
10 μ g/ml (final volume: 200–300 μ l), heated at 70 °C for 3 min, and then cooled on ice for 1 to 2 min. Before
IFNγ stimulation, 50–200 ng/ml aptamer (pre-incubated in DMEM/10% FCS at 37 °C overnight or not) and 2 ng/
ml IFNγ were incubated together at 37 °C for 10 min in DMEM/10% FCS. This mixture was then added to the
MDA-MB-231 cells, as described above.

Preparation for FACS Analysis.

After stimulation and washing, the cells were resuspended in 1 ml of 2%
paraformaldehyde (Electron Microscopy Sciences) for 10 min at room temperature, centrifuged, and resuspended
in 1 ml of ice-cold 90% methanol. The cells were incubated for 30 to 60 min or up to 72 h (see Supplementary Fig. 4)
at 4 °C in the dark. After centrifugation, the cells were washed twice with 500 μ l FACS buffer (1 × PBS pH 7.4
with 0.1% sodium azide and 0.1% BSA), incubated in 100 μ l of FACS buffer containing 7.5 μ l of anti-P-Stat-1 (BD
Phosflow PE mouse anti-Stat-1 pY701) for 30 to 60 minutes at 4 °C in the dark, and washed twice with 500 μ l of
FACS buffer. The cells were resuspended in 500 μ l FACS buffer and analyzed by flow cytometry (De Novo software, FCS Express, version 3).
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